Evaxion A (EVAX) Net Income towards Common Stockholders (2020 - 2026)
Evaxion A (EVAX) posted Net Income towards Common Stockholders of -$3.6 million for Q1 2026, up 38.68% on a QoQ basis from -$5.9 million in Q4 2025, and down 129.68% year-over-year from $12.2 million in Q1 2025.
Evaxion A (EVAX) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Evaxion A's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$3.6 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 129.68% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.8 million (up 26.85% YoY) and the FY2025 annual result came in at -$7.7 million, up 27.07% from the prior year.
- Net Income towards Common Stockholders was -$3.6 million for Q1 2026 at Evaxion A, up from -$5.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $5.8 million in Q1 2022 and bottomed at -$6.9 million in Q4 2022.
- A 5-year average of -$2.6 million and a median of -$4.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Peak annual rise in Net Income towards Common Stockholders reached 338.66% in 2025, while the deepest fall reached 232.33% in 2025.
- Evaxion A's Net Income towards Common Stockholders stood at -$6.9 million in 2022, then surged by 34.18% to -$4.5 million in 2023, then gained by 19.77% to -$3.6 million in 2024, then tumbled by 63.08% to -$5.9 million in 2025, then surged by 38.68% to -$3.6 million in 2026.
- Business Quant data shows EVAX's Net Income towards Common Stockholders at -$3.6 million in Q1 2026, -$5.9 million in Q4 2025, and $4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | -0.68 |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Evaxion A | 1.24 Bn | 1.24 Bn | - | -3.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.63 Mn |
| Dec 31, 2025 | -5.92 Mn |
| Sep 30, 2025 | 4.62 Mn |
| Jun 30, 2025 | -4.83 Mn |
| Mar 31, 2025 | -1.58 Mn |
| Dec 31, 2024 | -3.63 Mn |
| Sep 30, 2024 | -1.94 Mn |
| Jun 30, 2024 | -6.20 Mn |
| Mar 31, 2024 | 1.19 Mn |
| Dec 31, 2023 | -4.52 Mn |
| Sep 30, 2023 | -5.68 Mn |
| Jun 30, 2023 | -5.68 Mn |
| Mar 31, 2023 | -6.24 Mn |
| Dec 31, 2022 | -6.87 Mn |
| Sep 30, 2022 | 5.74 Mn |
| Jun 30, 2022 | -4.77 Mn |
| Mar 31, 2022 | 5.79 Mn |
| Dec 31, 2021 | -8.37 Mn |
| Sep 30, 2021 | 16.16 Mn |
| Jun 30, 2021 | -10.91 Mn |